

Six Current Research Projects Directly Measuring Effect of Factor Xa Inhibitors on Progression of Atherosclerotic Plaque - 20170505

Vascular Calcification and Stiffness Induced by Oral Anticoagulation (VICTORIA)

Sponsor: University Hospital, Angers

Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)

ClinicalTrials.gov number NCT02161965

<https://clinicaltrials.gov/ct2/show/NCT02161965>

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

Sponsor: Los Angeles Biomedical Research Institute

Estimated Primary Completion Date: Feb 2017 (Final data collection date for primary outcome measure)

ClinicalTrials.gov number NCT02376010

<https://clinicaltrials.gov/ct2/show/NCT02376010>

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Sponsor: Los Angeles Biomedical Research Institute

Estimated Primary Completion Date: Oct 2016 (Final data collection date for primary outcome measure)

ClinicalTrials.gov number NCT02090075

<https://clinicaltrials.gov/ct2/show/NCT02090075>

Pleotropic Effect of New Oral Anticoagulants

Sponsor: Kyunghee University Medical Center

Estimated Primary Completion Date: Sep 2017 (Final data collection date for primary outcome measure)

ClinicalTrials.gov number NCT02544932

<https://clinicaltrials.gov/ct2/show/NCT02544932>

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

Sponsor: Bayer

Completion Date: Study was stopped early "...based on the recommendation of the study's independent Data Monitoring Committee (DMC), as the primary MACE endpoint has reached its pre-specified criteria for superiority...A complete analysis of the data from the COMPASS trial is expected to be presented at a medical meeting in 2017." <https://www.jnj.com/media-center/press-releases/phase-3-compass-study-of-xarelto-rivaroxaban-stopping-early-for-efficacy-study-meets-primary-endpoint-of-prevention-of-major-adverse-cardiac-events-in-patients-with-coronary-artery-disease-or-peripheral-artery-disease>

<https://clinicaltrials.gov/ct2/show/NCT01776424>

Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients

Sponsor: Onze Lieve Vrouw Hospital

Estimated Primary Completion Date: Nov 2018 (Final data collection date for primary outcome measure)

ClinicalTrials.gov number NCT02610933

<https://clinicaltrials.gov/ct2/show/NCT02610933>